We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+13.54%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$5.12B
AUM Growth
-$493M
Cap. Flow
-$785M
Cap. Flow %
-15.35%
Top 10 Hldgs %
51.39%
Holding
136
New
20
Increased
23
Reduced
33
Closed
42

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$101M
2
RLAY icon
Relay Therapeutics
RLAY
+$70.2M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$59.9M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$39.8M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$33.2M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$122M
2
ACLX
Arcellx
ACLX
+$95.6M
3
BSX icon
Boston Scientific
BSX
+$93.3M
4
FOLD
Amicus Therapeutics
FOLD
+$90.7M
5
ATXS
Astria Therapeutics
ATXS
+$84.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OBIO icon
51
Orchestra BioMed
OBIO
$223M
$21.4M 0.42%
5,037,906
-89,350
-2% -$380K
RAPP
52
Rapport Therapeutics
RAPP
$1.92B
$21.1M 0.41%
673,923
– –
DBVT
53
DBV Technologies
DBVT
$880M
$20.1M 0.39%
+964,391
New +$20.1M
LONA
54
LeonaBio Inc
LONA
$73.4M
$19.1M 0.37%
1,859,322
– –
AVR
55
Anteris Technologies
AVR
$812M
$19M 0.37%
3,425,476
+1,750,000
+104% +$10.1M
STRO icon
56
Sutro Biopharma
STRO
$393M
$17.8M 0.35%
+715,307
New +$12.9M
TNGX icon
57
Tango Therapeutics
TNGX
$4.5B
$16.9M 0.33%
808,153
+295,118
+58% +$4.11M
CTNM
58
Contineum Therapeutics
CTNM
$524M
$16.4M 0.32%
1,255,592
-209,000
-14% -$2.8M
PALI icon
59
Palisade Bio
PALI
$328M
$15.6M 0.31%
8,928,149
-3,121,851
-26% -$5.68M
OCS icon
60
Oculis Holding
OCS
$761M
$13.1M 0.26%
493,827
– –
IRTC icon
61
iRhythm Holdings
IRTC
$3.79B
$12.4M 0.24%
105,026
-2,974
-3% -$429K
ADGM
62
Adagio Medical Holdings
ADGM
$11.8M
$11M 0.22%
9,876,576
– –
EVMN
63
Evommune Inc
EVMN
$422M
$10.3M 0.2%
+448,350
New +$10.1M
PHAT icon
64
Phathom Pharmaceuticals
PHAT
$875M
$10.3M 0.2%
+925,000
New +$11.7M
NMRA icon
65
Neumora Therapeutics
NMRA
$296M
$9.95M 0.19%
+5,104,097
New +$13.2M
OMDA
66
Omada Health Inc
OMDA
$1.41B
$9.88M 0.19%
786,330
-1,610,000
-67% -$22.2M
NBIX icon
67
Neurocrine Biosciences
NBIX
$17.2B
$8.57M 0.17%
65,050
-266,000
-80% -$35.3M
BBNX
68
Beta Bionics
BBNX
$753M
$8.45M 0.17%
842,944
+240,000
+40% +$3.55M
IRD
69
Opus Genetics
IRD
$271M
$8.35M 0.16%
1,835,842
-2,489,158
-58% -$8.61M
BLLN
70
BillionToOne Inc
BLLN
$5.9B
$7.25M 0.14%
91,812
+19,000
+26% +$1.56M
TWST icon
71
Twist Bioscience
TWST
$5.68B
$7.13M 0.14%
+150,000
New +$6.73M
SRZN icon
72
Surrozen
SRZN
$241M
$6.68M 0.13%
+229,393
New +$5.5M
AGMB
73
AgomAb Therapeutics NV
AGMB
$607M
$6.29M 0.12%
+600,000
New +$8.5M
EOLS icon
74
Evolus
EOLS
$371M
$5.29M 0.1%
+1,286,862
New +$6.24M
COGT icon
75
Cogent Biosciences
COGT
$6.48B
$4.66M 0.09%
121,082
– –
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Perceptive Advisors held 136 positions worth $5.12B, down 8.8% from $5.61B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors withdrew a net $785M in Q1 2026, closing 42 positions and reducing 33 holdings. Its most notable exit was Exact Sciences, an estimated $122M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Ionis Pharmaceuticals worth $37.8M.

  • Perceptive Advisors's largest Q1 2026 buy was Ionis Pharmaceuticals: 504,000 shares worth $37.8M.
  • Perceptive Advisors added most to Ascendis Pharma A/S in Q1 2026, an estimated $101M increase.
  • Perceptive Advisors's biggest Q1 2026 reduction was Apogee Therapeutics, cutting an estimated $57.4M.
  • Perceptive Advisors fully exited Exact Sciences in Q1 2026, selling an estimated $122M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $5.12B portfolio in Q1 2026.
  • Perceptive Advisors opened 20 new positions and closed 42 in Q1 2026.
  • Perceptive Advisors's portfolio value fell 8.8% quarter-over-quarter to $5.12B.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.